Pharmafile Logo
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • - PMLiVE
  • Communiqué 53 Cover Image

Gilotrif

- PMLiVE

Roche’s Tecentriq gets FDA Priority Review for specific stage 3 colon cancer

Over one million people are diagnosed globally each year and around 30% of stage 3 patients relapse within five years

- PMLiVE

Roche and Nurix Therapeutics to partner in $2.3bn deal

The companies will co-develop and co-commercialise bexobrutideg across malignant haematology, immunology and neurology

- PMLiVE

Bristol Myers Squibb and SystImmune announce phase 3 results for antibody-drug conjugate

The drug showed improvements in overall survival and progression-free survival in two cancers

- PMLiVE

Pfizer and Innovent Biologics agree on deal worth up to $10.5bn

The companies plan to research and develop 12 new cancer treatments

Roadmap visual

Where it all began – why we developed The Experience Gap

Learn how The Experience Gap was developed to help sponsors, CROs and site teams improve clinical trial participation by identifying friction points, enhancing patient experience, and driving better recruitment and...

Cuttsy + Cuttsy

The Experience Gap hero image

Cuttsy+Cuttsy launches a practical roadmap to enhance clinical trial participant experience

Cuttsy+Cuttsy has launched The Experience Gap, a practical roadmap designed to help clinical trial teams improve participant engagement, support and retention across the full study journey.

Cuttsy + Cuttsy

- PMLiVE

GSK signs agreement with Protas to streamline clinical trials

The new three-year agreement builds on an existing two-year relationship

- PMLiVE

Boehringer and Immunitas agree on licensing deal for chronic inflammatory and autoimmune diseases

The agreement strengthens Boehringer Ingelheim’s growing immunology pipeline

- PMLiVE

Biogen agrees $850m felzartamab rights deal with TJ Biopharma

The agreement gives Biogen full global rights to the investigational antibody across immune-mediated diseases

- PMLiVE

myTomorrows partners with Rare Disease Research to boost rare disease referrals

The collaboration aims to improve patient identification and access to clinical trials

- PMLiVE

AstraZeneca reports positive phase 3 data for tozorakimab in COPD

COPD affects nearly 400 million people globally and is the third leading cause of death worldwide

- PMLiVE

Shionogi starts phase 2 clinical trial for Pompe Disease

The rare disease affects around one in every 22,000 people worldwide

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links